Here are 1-2 brief analogies for Pediatrix Medical (MD):

• Pediatrix Medical is like TeamHealth for women's and children's subspecialty doctors, providing specialized medical staffing and management for hospitals.
• It's a national network of maternal-fetal and pediatric specialists, similar to how DaVita is a national network for kidney dialysis.

• Neonatal Care Services: Provides clinical care for premature or complicated babies within hospital units, delivered by neonatal physician subspecialists and nurse practitioners.
• Maternal-Fetal Care Services: Offers inpatient and office-based clinical care to expectant mothers and unborn babies through maternal-fetal medicine subspecialists and other clinicians.
• Pediatric Cardiology Care Services: Delivers inpatient and office-based care for fetuses, infants, children, and adolescents with congenital heart defects and acquired heart disease.
• Other Pediatric Subspecialty Care Services: Includes specialized care from pediatric intensivists, hospitalists, surgeons, ophthalmologists, and ear, nose, and throat physicians.
• Hospital Support Services: Provides support in areas such as pediatric emergency rooms, labor and delivery, and nursery/pediatric departments within hospitals.

Pediatrix Medical (symbol: MD) primarily provides medical care services directly to individuals.

Its major customer categories include:

• Newborns and Infants: Patients receiving neonatal care due to prematurity or complications.
• Expectant Mothers and Unborn Babies: Patients receiving maternal-fetal care, including inpatient and office-based clinical care.
• Children and Adolescents: Patients receiving pediatric cardiology care for congenital or acquired heart defects, as well as care from other pediatric subspecialists such as intensivists, hospitalists, surgeons, ophthalmologists, and ear, nose, and throat physicians.

Mark S. Ordan, Chair of the Board of Directors and Chief Executive Officer

Mark S. Ordan was appointed Chair of the Board of Directors and Chief Executive Officer of Pediatrix Medical Group in January 2025, having previously served as CEO from July 2020 to December 2022 and then as Executive Chair of the Board. He is recognized for his extensive experience in transforming business operations. Mr. Ordan founded and served as CEO of Fresh Fields Market, which he later merged with Whole Foods Market in 1996. He has held numerous CEO roles at other public companies, including Quality Care Properties, Inc., Washington Prime Group Inc., Sunrise Senior Living, Inc., The Mills Corporation, and Balducci's. Notably, he was instrumental in the sale of The Mills Corporation to Simon Property Group and Farallon Capital Management in 2007, and he led the turnaround and sale of Sunrise Senior Living, Inc. to Health Care REIT and KKR in 2013. His leadership at Quality Care Properties, Inc. also culminated in its sale to Welltower Inc. and ProMedica Health System. Mr. Ordan currently serves on the Board of Directors of The Carlyle Group as Lead Independent Director, demonstrating a pattern of managing or being involved with companies backed by private equity firms.

Kasandra Rossi, Executive Vice President, Chief Financial Officer and Treasurer

Kasandra Rossi was appointed Executive Vice President, Chief Financial Officer and Treasurer in October 2024. She joined Pediatrix in December 2009 and has held various senior-level accounting, finance, and treasury positions within the company, including Senior Vice President, Financial Reporting and Assistant Treasurer. Before joining Pediatrix, Ms. Rossi served in accounting and finance roles at other public companies in South Florida, such as Office Depot, Inc. and Republic Services, Inc., from July 2003 to December 2009. From September 1999 to July 2003, she was a member of the assurance practice of Ernst & Young, LLP, providing services to clients in various industries, including healthcare, private equity, and aviation.

Mary Ann E. Moore, Executive Vice President, General Counsel, Chief Administrative Officer and Secretary

Mary Ann E. Moore assumed the role of Chief Administrative Officer in August 2024, in addition to her existing appointments as Executive Vice President, General Counsel, and Secretary since October 2022. She joined Pediatrix in 2006 as Associate General Counsel and has since held several senior positions within the Legal Department. Prior to her tenure at Pediatrix, Ms. Moore served as Senior Counsel for Tenet Healthcare Corporation in South Florida. Her background also includes experience with Adventist Health System and in private legal practice.

Greg Neeb, Executive Vice President, Chief Investment and Strategy Officer

Greg Neeb was appointed Executive Vice President, Chief Investment and Strategy Officer in August 2025. He is the founder of Neeb Management LLC and Neeb Investments LLC, healthcare and real estate advisory and investment firms established in 2013. Mr. Neeb’s extensive experience includes serving as President and Chief Investment Officer of Quality Care Properties, Inc. from 2016 to 2018, which was later sold to Welltower Inc. and ProMedica Health System. From 2008 to 2013, he was the Chief Investment and Administrative Officer for Sunrise Senior Living, Inc., playing a key role in its sale to Welltower Inc. and Kohlberg Kravis Roberts & Co. LP. Earlier in his career, from 1995 to 2007, Mr. Neeb was Chief Investment Officer for The Mills Corporation, which was sold to Simon Property Group and Farallon Capital Management. His background demonstrates a consistent involvement in managing and selling companies, including those with private equity backing.

Nanette Sanders, Executive Vice President, National Operations

Nanette Sanders serves as the Executive Vice President of National Operations for Pediatrix Medical Group. She joined the company in 1997, when it was known as Mednax, as a Regional Manager for the Managed Care Division. Throughout her career at Pediatrix, Ms. Sanders has held various leadership roles, including Regional President, West Coast, Regional Vice President, West Market, and Director of Operations in the Pacific Region. She brings over 35 years of experience in the healthcare industry, encompassing hospitals, private practices, and managed care sectors.

Key Risks to Pediatrix Medical (MD)

1. Reliance on Highly Specialized Medical Professionals: Pediatrix Medical's business model depends heavily on recruiting and retaining a broad network of highly specialized medical professionals, including neonatal physician subspecialists, maternal-fetal medicine subspecialists, pediatric cardiologists, and other pediatric subspecialists. A shortage of these professionals, increased competition for their services, or challenges in retention could significantly impact the company's ability to deliver care and grow its services.
2. Dependence on Hospital Contracts: The company provides its services primarily within specific units at hospitals, including pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. This indicates a substantial reliance on contracts with hospitals. The loss of significant hospital contracts, inability to renew existing agreements on favorable terms, or pressure on contract pricing could materially affect the company's operations and financial performance.
3. Changes in Healthcare Reimbursement Policies and Regulations: As a healthcare services provider, Pediatrix Medical is susceptible to changes in government and private insurance reimbursement policies, including reductions in reimbursement rates, changes in coverage criteria, or shifts in payment models. Additionally, evolving healthcare regulations could increase compliance costs or restrict operational flexibility, negatively impacting profitability and service delivery.

Neonatal Care Services

Maternal-Fetal Care Services

Pediatric Cardiology Care Services

Other Pediatric Subspecialty Care Services

Pediatrix Medical (MD) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

1. Favorable Payer Mix and Increased Patient Acuity: The company anticipates continued benefit from a favorable payer mix and higher patient acuity within its neonatology segment. This leads to improved reimbursement-related factors and growth in same-unit pricing, contributing to top-line performance despite potential flat patient volumes.
2. Strategic Acquisitions: Pediatrix Medical is pursuing an inorganic growth strategy, focusing on strategic acquisitions in its core and adjacent service areas to expand its capacity and patient volumes. The company is actively exploring further practice acquisitions and expansion opportunities.
3. Expansion of Core Specialties and Telemedicine: The company is committed to expanding its presence within core specialties, including Neonatal Intensive Care Units (NICUs), maternal-fetal medicine, and OB hospital medicine programs. Additionally, Pediatrix Medical is exploring growth opportunities through the strategic use of telemedicine.
4. Enhanced Revenue Cycle Management (RCM) and Contract Administrative Fees: Improvements in revenue cycle management collections, coupled with an favorable payer mix, increased patient acuity, and higher contract administrative fees from hospital partners, are expected to support an increase in net patient service revenues, even if patient volumes and general pricing remain stable.

Share Repurchases

• Pediatrix Medical Group authorized a share repurchase program of up to $250 million of its outstanding common stock on August 18, 2025, with a three-year term.
• The company used $64.0 million for share repurchases in the fourth quarter of 2025, which reduced shares outstanding to approximately 83 million.
• Pediatrix Medical Group also used $20.9 million for share repurchases in the third quarter of 2025.

Share Issuance

• On March 1, 2026, an executive vice president received 39,925 shares as a performance-based award from a program established in March 2023, with 26,931 shares withheld for tax obligations upon vesting.
• The weighted average shares outstanding for the year ended December 31, 2025, was 85.3 million, compared to 83.3 million for 2024.
• Weighted average shares outstanding were 82.2 million for the year ended December 31, 2023.

Outbound Investments

• Pediatrix Medical Group utilized $19.2 million for acquisition activity in the third quarter of 2025.
• The company used $5.0 million to fund a practice acquisition in the fourth quarter of 2023.
• In 2024, Pediatrix Medical Group added one maternal-fetal medicine practice while completing plans to exit most office-based practices and its primary and urgent care service lines.

Capital Expenditures

• Pediatrix Medical Group’s capital expenditures were $5.3 million in the fourth quarter of 2025 and $5.3 million in the third quarter of 2025.
• The company reported $3.4 million in capital expenditures for the fourth quarter of 2024.
• Capital expenditures totaled $9.0 million in the fourth quarter of 2023.